Supported by a peptide complex of the inactive mutant Glu424Ala, the simulated four-step mechanism of the prostate cancer-related glutamate carboxypeptidase II (GCPII) exhibited a 20% higher free activation barrier [93]. This evidence concerns the gene FOLH1 and prostate cancer.